Serum antimüllerian hormone levels are independently related to miscarriage rates after in vitro fertilization–embryo transfer Bruno Tarasconi, M.D.,

Slides:

Advertisements

Similar presentations

Essure hysteroscopic tubal occlusion device for the treatment of hydrosalpinx prior to in vitro fertilization-embryo transfer in patients with a contraindication.

Advertisements

Effect of detorsion alone and in combination with enoxaparin therapy on ovarian reserve and serum antimüllerian hormone levels in a rat ovarian torsion.

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D.

Changes in serum cortisol and prolactin associated with acupuncture during controlled ovarian hyperstimulation in women undergoing in vitro fertilization–embryo.

New look at endometrial echogenicity: objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization–embryo transfer

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage.

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Risks of tubo-ovarian abscess in cases of endometrioma and assisted reproductive technologies are both under- and overreported Claire Villette, M.D.,

Ureteral injury after transvaginal ultrasound-guided oocyte retrieval: a complication of in vitro fertilization-embryo transfer that may lurk undetected.

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Antimüllerian hormone: correlation with age and androgenic and metabolic factors in women from birth to postmenopause Linlin Cui, M.D., Ph.D., Yingying.

Robot-assisted laparoscopy for infertility treatment: current views

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids Isabelle.

Temporal trends in clomiphene citrate use: a population-based study

Initial experience with a risk-sharing in vitro fertilization–embryo transfer program with novel features Jacques P. Stassart, M.D., Romaine B. Bayless,

The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Modified natural cycle in in vitro fertilization

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.

Two interesting cases of ovarian pregnancy after in vitro fertilization–embryo transfer and its successful laparoscopic management Selvaraj Priya, M.D.,

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Remembering Gary D. Hodgen, Ph.D.: 1943–2005

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling.

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Sperm deoxyribonucleic acid damage in normozoospermic men is related to age and sperm progressive motility Stephanie Belloc, Pharm.D., Moncef Benkhalifa,

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

From partner's desk to iPad

Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles Karin.

Nondominant small follicles are a promising source of mature oocytes in modified natural cycle in vitro fertilization and embryo transfer Shokichi Teramoto,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Pietro Santulli, M. D. , Bruno Borghese, M. D. , Ph. D

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

Birth records from Swiss married couples analyzed over the past 35 years reveal an aging of first-time mothers by 5.1 years while the interpregnancy interval.

Clinical uses of anti-Müllerian hormone assays: pitfalls and promises

Uterorelaxing effects of vaginal progesterone: comparison of two methodologies for assessing uterine contraction frequency on ultrasound scans Jean-Marc.

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Brian W. Whitcomb, Ph. D. , Enrique F. Schisterman, Ph. D. , Mark A

Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome? Luis.

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer Mohamed.

Increased serum polychlorobiphenyl levels in Belgian women with adenomyotic nodules of the rectovaginal septum Jean-François Heilier, Pharm.D., Anh Thi.

Interleukin-1β and interleukin-1α may affect the implantation rate of patients undergoing in vitro fertilization–embryo transfer Evdokia E Karagouni,

Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr Murat Arslan, M.D.,

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

In vitro sildenafil citrate use as a sperm motility stimulant

Treatment of heterotopic cervical pregnancy after in vitro fertilization–embryo transfer by using transvaginal ultrasound–guided aspiration and instillation.

Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer Julien Mancini, M.D., M.P.H.,

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Norbert.

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome Ernesto Bosch,

Hulusi B Zeyneloglu, M.D., Aydin Arici, M.D., David L Olive, M.D.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Dominique de Ziegler, M. D. , Paul Pirtea, M. D. , Daniela Galliano, M

Presentation transcript:

Serum antimüllerian hormone levels are independently related to miscarriage rates after in vitro fertilization–embryo transfer Bruno Tarasconi, M.D., Teddy Tadros, M.D., Jean-Marc Ayoubi, M.D., Ph.D., Stephanie Belloc, Pharm.D., Dominique de Ziegler, M.D., Renato Fanchin, M.D., Ph.D. Fertility and Sterility Volume 108, Issue 3, Pages 518-524 (September 2017) DOI: 10.1016/j.fertnstert.2017.07.001 Copyright © 2017 Terms and Conditions

Figure 1 Miscarriage rates in the different age and antimüllerian hormone (AMH) groups. Miscarriage rates were higher in the low AMH group, as follows: 21% (9/43) in the low AMH group, 16% (44/284) in the medium AMH group, and 13% (18/140) in the high AMH group in the ≤33 years age group; 33% (13/41), 15% (28/185), and 17% (10/61), respectively, in the 34–36 years age group; and 35% (23/68), 26% (46/182), and 18% (10/56), respectively, in the ≥37 years age group. However, differences reached statistical significance only between the low and medium AMH groups in the 34–36 years age group and between the low and high AMH groups in the ≥37 years age group. Fertility and Sterility 2017 108, 518-524DOI: (10.1016/j.fertnstert.2017.07.001) Copyright © 2017 Terms and Conditions